Quick Answer
Lantern Pharma Inc. reported R&D Expense of $11.51 million for fiscal year 2025.
Lantern Pharma Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $11.51M | -28.6% |
| 2024 | $16.13M | +35.6% |
| 2023 | $11.89M | +38.3% |
| 2022 | $8.60M | +13.6% |
| 2021 | $7.57M | +237.5% |
| 2020 | $2.24M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.44M | -34.4% | -20.6% |
| June 30, 2025 | $3.07M | -21.1% | -6.0% |
| March 31, 2025 | $3.26M | -23.2% | -12.2% |
| September 30, 2024 | $3.72M | +68.2% | -4.4% |
| June 30, 2024 | $3.89M | +9.3% | -8.5% |
| March 31, 2024 | $4.25M | +66.5% | +92.4% |
| September 30, 2023 | $2.21M | +214.7% | -37.9% |
| June 30, 2023 | $3.56M | +19.1% | +39.4% |
- Lantern Pharma Inc. showed a decrease of -28.6% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Lantern Pharma Inc.’s r&d expense has grown by 413.3% (from $2.24 million to $11.51 million).
- The most recent figure is from Lantern Pharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: